Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.84 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | RARG | P13631 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113884 | 0.92 | CDC7 (1.00) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL4485015 | 0.91 | CDC7 (0.71) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL4740819 | 0.86 | CDC7 (0.85) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL3056066 | 0.86 | CDC7 (0.65) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL15716809 | 0.85 | CDC7 (0.63) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL975727 | 0.83 | CDC7 (0.86) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL8823109 | 0.82 | CDC7 (0.61) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL16039727 | 0.82 | KDM4E (0.68) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL27920107 | 0.82 | KDM4E (0.67) | CDC7DBF4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL8823093 | 0.82 | SMN1; SMN2 (0.63) | CDC7DBF4SMN1; SMN2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | claimed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | claimed |
| CN-103333134-A | 2-(3-cyano-4-alkoxy) phenyl-4-substituted thiazole-5-formic acid compound, composition as well as preparation methods and applications thereof | UNIV SHENYANG PHARMACEUTICAL | 2013-10-02 | — | — | CN | claimed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| CN-103333134-B | 2-(3-cyano group-4-alkoxyl group) phenyl-4-substituted thiazole-5-formic acid compound, composition and method of making the same and purposes | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-02-24 | — | — | CN | disclosed |
| WO-2014160197-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2217588-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | CDC7 3776/4885DBF4 1455/4885SMN1; SMN2 3624/4885 |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | CDC7 3287/4885DBF4 3834/4885SMN1; SMN2 22/4885 |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | CDC7 3287/4885DBF4 3834/4885SMN1; SMN2 22/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | CDC7 2663/4885DBF4 1700/4885SMN1; SMN2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.